Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients

被引：0

作者：

Wahid, Mohd ^{[1
,10
]}

Mandal, Raju K. ^{[1
]}

Jawed, Arshad ^{[1
]}

Alsulimani, Ahmad ^{[2
]}

Hashem, Anwar M. ^{[3
,4
]}

Harakeh, Steve ^{[5
,6
]}

Hussain, Arif ^{[7
]}

Fagoonee, Sharmila ^{[8
]}

Pellicano, Rinaldo ^{[9
]}

Haque, Shafiul ^{[1
,10
]}

机构：

[1] Jazan Univ, Coll Nursing & Allied Hlth Sci, Res & Sci Studies Unit, Jazan, Saudi Arabia

[2] Jazan Univ, Coll Appl Med Sci, Med Lab Technol Dept, Jazan, Saudi Arabia

[3] King Abdulaziz Univ, Fac Med, Dept Med Microbiol & Parasitol, Jeddah, Saudi Arabia

[4] King Abdulaziz Univ, King Fahd Med Res Ctr, Vaccines & Immunotherapy Unit, Jeddah, Saudi Arabia

[5] King Abdulaziz Univ, Fac Med, King Fahd Med Res Ctr, Jeddah, Saudi Arabia

[6] King Abdulaziz Univ, Fac Med, Yousef Abdullatif Jameel Chair Prophet Med Applica, Jeddah, Saudi Arabia

[7] Manipal Acad Higher Educ, Sch Life Sci, Dubai, U Arab Emirates

[8] Mol Biotechnol Ctr, Inst Biostruct & Bioimaging, CNR, Turin, Italy

[9] Molinette Mauriziano Hosp, Unit Gastroenterol, Turin, Italy

[10] Jazan Univ, Coll Nursing & Allied Hlth Sci, Res & Sci Studies Unit, Jazan 45142, Saudi Arabia

来源：

BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS | 2023年 / 39卷 / 02期

关键词：

Checkpoint inhibitors; median progression free survival; metastatic melanoma; metastasize; nivolumab; RESISTANCE; PD-1; MUTATIONS; TOLERANCE; MECHANISM; THERAPY; PATHWAY; CTLA-4; CELLS;

D O I：

10.1080/02648725.2022.2147683

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Metastatic melanoma has less frequency, but considered as the most dreaded cancer. The combination of nivolumab & ipilimumab is proving their mettle in treating metastatic melanoma. The patients when administered with the combination of nivolumab & ipilimumab have shown improved median progression free survival, objective response rate and overall survival rate compared with nivolumab and ipilimumab monotherapy. The combination shrinks the tumor cells by attacking different checkpoints viz. CTLA-4 and PD-L1, respectively. The combination treatment reveals reduced disease progression and suggests nivolumab's non-cross resistant nature. The median progression free survival in "nivolumab plus ipilimumab" group has shown an increase of 66.7% and 296.6% in comparison to nivolumab and ipilimumab monotherapy. The other parameter viz. objective response rate improvement is equivalent to almost 14% and 38.6% when compared to nivolumab and ipilimumab monotherapy, respectively.

引用

页码：421 / 434

页数：14

共 50 条

[1] Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, Hussein A.
Forsyth, Peter A.
Algazi, Alain
Hamid, Omid
Hodi, F. Stephen
Moschos, Stergios J.
Khushalani, Nikhil I.
Lewis, Karl
Lao, Christopher D.
Postow, Michael A.
Atkins, Michael B.
Ernstoff, Marc S.
Reardon, David A.
Puzanov, Igor
Kudchadkar, Ragini R.
Thomas, Reena P.
Tarhini, Ahmad
Pavlick, Anna C.
Jiang, Joel
Avila, Alexandre
Demelo, Sheena
Margolin, Kim
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (08): : 722 - 730
[2] Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma
Parakh, Sagun
Randhawa, Manreet
Nguyen, Bella
Warburton, Lydia
Hussain, Mohammad Akhtar
Cebon, Jonathan
Millward, Michael
Yip, Desmond
Ali, Sayed
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (01) : 26 - 30
[3] Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
Reichert, Constance
Baldini, Capucine
Mezghani, Sarah
Maubec, Eve
Longvert, Christine
Mortier, Laurent
Quereux, Gaelle
Jannic, Arnaud
Machet, Laurent
de Quatrebarbes, Julie
Nardin, Charlee
Beneton, Nathalie
Amini Adle, Mona
Funck-Brentano, Elisa
Descamps, Vincent
Hachon, Lorry
Malissen, Nausicaa
Baroudjian, Barouyr
Brunet-Possenti, Florence
[J]. CANCERS, 2023, 15 (17)
[4] Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Mansouri, Alireza
Moraes, Fabio Y.
Zadeh, Gelareh
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2177 - 2178
[5] Ipilimumab improves survival in metastatic melanoma patients
Hodi, F. S.
O'Day, S. J.
McDermott, D. F.
[J]. IMMUNOTHERAPY, 2011, 3 (08) : 928 - 929
[6] Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
Asher, Nethanel
Ben-Betzalel, Guy
Lev-Ari, Shaked
Shapira-Frommer, Ronnie
Steinberg-Silman, Yael
Gochman, Neta
Schachter, Jacob
Meirson, Tomer
Markel, Gal
[J]. CANCERS, 2020, 12 (08) : 1 - 18
[7] Quality of Life of metastatic Melanoma Patients receiving combined Immune Checkpoint Inhibition with Ipilimumab and Nivolumab
Grote, Carolin
Bohne, Ann-Sophie
Petersen, Henrike
Rohde, Hanna
Kaehler, Katharina
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 159 - 159
[8] Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain Reply
Tawbi, Hussein A.
Chung, Caroline
Margolin, Kim
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2178 - 2178
[9] Neurologic Complications Effects of ipilimumab and nivolumab therapy in patients with metastatic melanoma
Latchman, Jessica
Guastella, Ann
Tofthagen, Cindy
[J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2019, 23 (04) : 355 - 358
[10] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J.
Chiarion-Sileni, V.
Gonzalez, R.
Grob, J. J.
Cowey, C. L.
Lao, C. D.
Schadendorf, D.
Dummer, R.
Smylie, M.
Rutkowski, P.
Ferrucci, P. F.
Hill, A.
Wagstaff, J.
Carlino, M. S.
Haanen, J. B.
Maio, M.
Marquez-Rodas, I.
McArthur, G. A.
Ascierto, P. A.
Long, G. V.
Callahan, M. K.
Postow, M. A.
Grossmann, K.
Sznol, M.
Dreno, B.
Bastholt, L.
Yang, A.
Rollin, L. M.
Horak, C.
Hodi, F. S.
Wolchok, J. D.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (01): : 23 - 34

← 1 2 3 4 5 →